The DOI matches its Crossref record.
Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients
Abstract
The optimal administration regimens of low molecular weight heparins (LMWHs) have not yet been established. The aim of this study was to compare the efficacy and safety of 2500 and 5000 Xal units of the LMWH dalteparin in patients undergoing elective general surgery for malignant and benign abdominal disease. Prophylaxis was started in the evening before surgery and given once-daily every evening thereafter. The study was designed as a prospective, randomized, double-blind, multicentre trial. Some 66.4 per cent of patients were operated on for a malignant disorder. The primary endpoint was deep vein thrombosis (DVT) detected with the fibrinogen uptake test. Bleeding complications were recorded and classified. Analysis was made both on an intention to treat basis and in patients given correct prophylaxis (86.3 per cent). A total of 2097 patients were randomized and 27 excluded after randomization. A technically correct fibrinogen uptake test was obtained in 1957 patients. The incidence of DVT was significantly lower in patients given 5000 Xal units, this being true for both correct prophylaxis (6.8 versus 13.1 per cent, P < 0.001), on an intention to treat basis (6.6 versus 12.7 per cent, P < 0.001), and in patients with malignant disease (8.5 versus 14.9 per cent, P < 0.001). Sixty-seven patients (3.2 per cent) died within 30 days with no difference between the groups. There were two cases of fatal pulmonary embolism. The frequency of bleeding complications in the whole series was higher in patients randomized to 5000 Xal units (4.7 versus 2.7 per cent, P = 0.02), although this was not the case in those operated on for malignant disease (4.6 versus 3.6 per cent, P not significant). Dalteparin in the dose of 5000 Xal units started in the evening before surgery has a good thromboprophylactic effect in high-risk general surgery at the cost of a small bleeding risk. In patients with malignant disease there was no increased risk of bleeding. The overall frequency of fatal pulmonary embolism with dalteparin is extremely low, even in this high-risk group of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationPrevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Prevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Self-citationPrevention of VTE in Nonorthopedic Surgical Patients
Gould, M. K., Garcia, D. A., Wren, S. M., Karanicolas, P. J., Arcelus, J. I., Heit, J. A., & Samama, C. M. (2012) · Chest · doi:10.1378/chest.11-2297 · Cited by 2,131
Lyman, G. H., Bohlke, K., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7351 · Cited by 1,371
Lyman, G. H., Khorana, A. A., Falanga, A., Clarke-Pearson, D., Flowers, C., Jahanzeb, M., Kakkar, A., Kuderer, N. M., Levine, M. N., Liebman, H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1283 · Cited by 952
Lyman, G. H., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., Gates, L. E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1118 · Cited by 713
Mismetti, P., Laporte, S., Darmon, J.-Y., Buchmüller, A., & Decousus, H. (2001) · Journal of British Surgery · doi:10.1046/j.0007-1323.2001.01800.x · Cited by 649
FARGE, D., DEBOURDEAU, P., BECKERS, M., BAGLIN, C., BAUERSACHS, R. M., BRENNER, B., BRILHANTE, D., FALANGA, A., GEROTZAFIAS, G. T., HAIM, N., et al. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12070 · Cited by 595
Cancer and venous thromboembolism
Prandoni, P., Falanga, A., & Piccioli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70207-2 · Cited by 540
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines
Mandalà, M., Falanga, A., & Roila, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr392 · Cited by 512
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
Falanga, A., Ay, C., Di Nisio, M., Gerotziafas, G., Jara-Palomares, L., Langer, F., Lecumberri, R., Mandala, M., Maraveyas, A., Pabinger, I., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.014 · Cited by 413
Prevention of Venous Thromboembolism
Clagett, G. P., Anderson, F. A., Geerts, W., Heit, J. A., Knudson, M., Lieberman, J. R., Merli, G. J., & Wheeler, H. B. (1998) · Chest · doi:10.1378/chest.114.5_supplement.531s · Cited by 378
Agnelli, G., Bergqvist, D., Cohen, A. T., Gallus, A. S., & Gent, M. (2005) · British Journal of Surgery · doi:10.1002/bjs.5154 · Cited by 337
Self-citation(1997) · British Journal of Surgery · doi:10.1046/j.1365-2168.1997.d01-3882.x · Cited by 296
Marras, L. C., Geerts, W. H., & Perry, J. R. (2000) · Cancer · doi:10.1002/1097-0142(20000801)89:3<640::aid-cncr20>3.0.co;2-e · Cited by 273
Methodological issues in trials assessing primary prophylaxis of venous thrombo-embolism
Thabut, G., Estellat, C., Boutron, I., Samama, C. M., & Ravaud, P. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi587 · Cited by 11
Metadata
- Authors
- Bergqvist, D., Burmark, U. S., Flordal, P. A., Frisell, J., Hallböökr, T., Hedberg, M., Horn, A., Kelty, E., Kvitting, P., Lindhagen, A., Ljungström, K. G., Mätzsch, T., Risberg, B., Syk, I., Törngren, S., Wellander, E., & Örtenwall, P.
- Venue
- Journal of British Surgery
- Publisher
- Oxford University Press (OUP)
- Published
- 1995-04-01
- Volume
- 82
- Issue
- 4
- Pages
- 496-501
- ISSN
- 0007-1323 (ISSN-L)
- 1365-2168
- OpenAlex
- W2119736254
- Cited by
- 218
- References
- 0
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.